Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Akebia Therapeutics, Inc. (AKBA) vs Organogenesis (ORGO)

Akebia Therapeutics, Inc. and Organogenesis are both Drug Manufacturers Specialty & Generic companies. Akebia Therapeutics, Inc. is the larger, with a market value of $254.7M against $207.1M — 1.2× the size. Akebia Therapeutics, Inc. grew revenue faster over the last twelve months: 7.52% against 6.50%. Akebia Therapeutics, Inc. has the higher net margin (−13.5% vs −22.2%) and the higher return on invested capital (0.00% vs −20.0%). Across the 20 metrics below, Akebia Therapeutics, Inc. leads on 11 and Organogenesis on 9.

Valuation

Metric AKBA ORGO Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.11 0.39 2.25
P/B 9.70 1.22 1.90
Price to free cash flow 6.03 8.64 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 0.62 0.33 2.56
Earnings yield (12.00%) (60.71%) (2.99%)
Free cash flow yield 16.59% 11.57% 0.00%

Profitability

Metric AKBA ORGO Drug Manufacturers Specialty & Generic median
Gross margin 79.63% 70.35% 53.94%
Operating margin (6.90%) (7.84%) 0.00%
Net margin (13.54%) (22.23%) 0.00%
Free cash flow margin 18.38% 4.56% 0.00%
Return on equity (109.38%) (53.31%) (0.40%)
Return on assets (8.53%) (23.44%) (3.32%)
Return on invested capital 0.00% (19.97%) 0.00%

Growth

Metric AKBA ORGO Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 7.52% 6.50% 10.01%
EPS growth (last fiscal year) 93.94% 1,600.00% —
Revenue growth, 5-year CAGR (4.33%) 10.77% 6.74%
Net income growth, 5-year CAGR 0.00% 3.04% 0.00%

Health

Metric AKBA ORGO Drug Manufacturers Specialty & Generic median
Debt to equity 1.98 0.07 0.05
Current ratio 1.43 3.52 2.31
Net debt to EBITDA (5.51) (1.14) 0.85

Dividend

Metric AKBA ORGO Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AKBA ORGO Drug Manufacturers Specialty & Generic median
Market cap 254.66m 207.13m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack